Assembly Concurrent Resolution 94 frames antimicrobial resistance (AMR) as a statewide public‑health crisis and asks state leaders to treat it as an urgent, sustained policy priority. The text does not impose new regulatory mandates; instead, it directs attention and asks state agencies and stakeholders to align on prevention, diagnostics, stewardship, and research funding.
Why it matters: AMR erodes the effectiveness of core therapies across human and veterinary medicine and requires cross‑sector coordination. By elevating AMR in state policy conversation, the resolution aims to push Medi‑Cal policy, public education, and interagency collaboration toward actions that improve diagnostics, preserve antibiotics, and reduce disparities in high‑risk and underserved communities.
At a Glance
What It Does
ACR 94 is a nonbinding concurrent resolution that recognizes AMR as a public health crisis and urges state health entities to coordinate on stewardship, diagnostics, public education, and funding for research and development. It asks agencies to encourage evidence‑based prescribing and to explore ways to make advanced diagnostic tools more accessible and affordable.
Who It Affects
Directly implicated parties include the Department of Public Health, the Department of Health Care Services (DHCS), the California Health and Human Services Agency, the State Medicaid (Medi‑Cal) program, health care providers and facilities, diagnostic developers and laboratories, and communities with limited access to care. Indirectly affected are agricultural and veterinary stakeholders whose practices influence resistance patterns.
Why It Matters
The resolution signals a statewide policy priority without creating new statutory requirements; that political and administrative signal can influence program guidance, coverage decisions, grantmaking priorities, and stakeholder collaboration. For program managers and compliance officers, it creates a roadmap for near‑term coordination and potential funding pursuits focused on diagnostics, stewardship, and equity.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
ACR 94 reads as a policy signal rather than a law. It opens by formally recognizing that drug‑resistant infections pose an urgent public‑health problem for California and argues that the response must be multipronged: surveillance, prevention, education, research, and equitable access to care.
The resolution then lays out a series of nonbinding requests to state entities to prioritize those areas.
On clinical practice and coverage, the text encourages integrating antimicrobial stewardship into the state’s Medicaid program, with an explicit emphasis on incentivizing the use of rapid diagnostic tests and adherence to evidence‑based prescribing. Separately, it asks state public‑health and health‑services agencies to work with federal partners, providers, and academic institutions to expand development and accessibility of advanced diagnostics, recognizing that testing availability is a bottleneck for appropriate therapy.The resolution also backs public education campaigns—calling for messaging about appropriate antibiotic use and the diagnostic role in better outcomes—and it specifically urges state agencies to explore funding mechanisms to support research and development, with a focus on underserved and high‑risk communities.
Finally, it instructs the Assembly Chief Clerk to send copies of the resolution to the Governor and named officials to promote awareness and interagency coordination.
The Five Things You Need to Know
California faces a significant AMR burden: the bill cites roughly 360,000 illnesses and about 4,500 deaths annually in the state attributable to resistant infections.
The resolution notes that approximately 60% of intensive care unit infections in California show resistance to key antibiotics, highlighting critical hospital impacts.
It references California policy history on antibiotics in agriculture, pointing to Senate Bill 27 and Senate Bill 1311 and a cited 7.1% reduction in extended‑spectrum cephalosporin resistance in human E. coli following prior livestock restrictions.
The text designates November 18–24 each year as World AMR Awareness Week and endorses public awareness efforts tied to that observance.
ACR 94 directs the Assembly Chief Clerk to transmit copies of the resolution to the Governor, the Secretary of California Health and Human Services, the directors of the State Department of Public Health and DHCS, the State Medicaid Director, and other stakeholders.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Frames AMR as an urgent public‑health problem
The preamble compiles national and state surveillance estimates, cites ICU resistance rates, and links human and animal antibiotic use to resistance. For practitioners and policy analysts, this matters because it sets the evidentiary baseline the Legislature used to justify action: the resolution’s facts are curated to emphasize hospital burden, community disparities, and cross‑sector drivers.
Encourages integrating stewardship into Medi‑Cal with diagnostic incentives
This clause asks DHCS and related bodies to incorporate antimicrobial stewardship into Medicaid policy and to include incentives for providers to adopt rapid diagnostics and evidence‑based prescribing. Practically, DHCS could interpret this as prompting program guidance, payment adjustments, prior‑authorization criteria, or performance incentives tied to antibiotic prescribing metrics—actions that would originate administratively rather than by statute.
Urges agency collaboration to expand access to advanced diagnostics
The resolution asks state health agencies to work with federal partners, providers, and academic researchers to improve development, accessibility, and affordability of advanced tests. The operative implications include coordinated procurement strategies, support for laboratory capacity, and alignment on reimbursement pathways—areas where administrative policy and federal grant programs can be leveraged to increase test availability.
Supports statewide campaigns to improve prescribing and public awareness
By endorsing public education, the text invites CDPH and partners to design messaging about appropriate antibiotic use and the value of diagnostics. That creates opportunities for targeted outreach—especially in high‑risk communities—and for metrics around reach and behavior change that funders or agencies might later adopt to judge program success.
Requests exploration of funding mechanisms for R&D and transmits the resolution to officials
The resolution explicitly urges CalHHS, CDPH, and DHCS to explore funding options for research and development initiatives, especially in underserved areas, and requires the Clerk to circulate the resolution to named officials. The practical consequence is twofold: agencies get a documented legislative prompt to prioritize federal and state funding opportunities, and stakeholders receive formal notice to coordinate responses or proposals.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Underserved and high‑risk communities — the resolution prioritizes funding exploration and education targeted to reduce disparities in access to diagnostics and effective treatment, which could improve outcomes where resources are thin.
- Medi‑Cal beneficiaries — if DHCS follows the encouragement with coverage or incentive changes, beneficiaries may receive faster, more accurate diagnoses and better‑targeted antibiotic therapy.
- Diagnostic developers and laboratories — the push to enhance accessibility and affordability of advanced tests creates market and funding signals that can accelerate development, validation, and scaling efforts.
- Hospitals and long‑term care facilities — existing stewardship programs stand to gain clearer state support and possible incentives tied to diagnostic use, which can reduce inappropriate prescribing and resistance pressure.
- Public‑health and academic institutions — the resolution’s emphasis on collaboration and research funding exploration opens avenues for grants, pilot projects, and data‑sharing partnerships.
Who Bears the Cost
- Department of Health Care Services and state agencies — the resolution asks them to explore funding and to coordinate activities, which requires staff time and may create unfunded program development obligations.
- Health care providers and clinical laboratories — adopting rapid diagnostics and reporting to stewardship programs can impose workflow changes, training and equipment costs, and documentation burdens unless Medi‑Cal reimbursement offsets them.
- Taxpayers and grantmakers — if agencies pursue new state funding or match federal grants for diagnostics or R&D, payors ultimately bear those costs; reallocating funds could crowd out other priorities.
- Diagnostic manufacturers — to meet affordability and accessibility goals they may need to lower prices or invest in distribution and validation, potentially squeezing margins for smaller firms.
- Long‑standing surveillance programs and local public‑health departments — implementing expanded surveillance or community outreach may require additional funding and coordination that local programs must absorb or request from the state.
Key Issues
The Core Tension
The central dilemma is between signaling urgency and actually funding action: ACR 94 elevates AMR as a policy priority and asks for coordination, but without statutory authority or dedicated funding it relies on administrative discretion and existing budgets—improving alignment on stewardship and diagnostics will require choices about who pays for new tests, incentives, and outreach, and those cost allocations will inevitably favor some stakeholders over others.
Two implementation ambiguities are immediate. First, the resolution urges ‘‘integration’’ of stewardship into Medi‑Cal and ‘‘incentives’’ for rapid diagnostics but provides no specificity on which payment levers (e.g., fee schedules, bundled payments, value‑based metrics, prior authorization) DHCS should use.
That leaves substantial discretion to administrators and creates uncertainty for providers deciding whether to invest in diagnostics before reimbursement paths are clarified.
Second, the resolution urges agencies to ‘‘explore’’ funding mechanisms for R&D, particularly in underserved communities, but does not identify likely sources or authorize state spending. Agencies must balance competitive federal grant timelines, existing state budget constraints, and the administrative cost of program design.
These gaps make outcomes dependent on subsequent administrative action, interagency prioritization, and available appropriations—factors the resolution does not control.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.